Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Zelluna raised NOK 58 million to advance its cancer therapy into Phase I trials.
Zelluna ASA completed a private placement and retail offering on November 3, 2025, raising NOK 58 million to advance its ZI-MA4-1 TCR-NK therapy into Phase I trials.
The company issued 5.5 million shares in the private placement and 315,639 via PrimaryBid, with share lending used for settlement.
A potential subsequent offering of up to 800,000 shares for existing shareholders is planned, pending approvals and market conditions.
The total new shares issued could reach 6.615 million, aiming to strengthen capital and support development of its off-the-shelf cancer therapy.
4 Articles
Zelluna recaudó 58 millones de NOK para avanzar en su terapia contra el cáncer en ensayos de Fase I.